e-Article
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
Document Type
article
Author
Tenforde, Mark W; Olson, Samantha M; Self, Wesley H; Talbot, H Keipp; Lindsell, Christopher J; Steingrub, Jay S; Shapiro, Nathan I; Ginde, Adit A; Douin, David J; Prekker, Matthew E; Brown, Samuel M; Peltan, Ithan D; Gong, Michelle N; Mohamed, Amira; Khan, Akram; Exline, Matthew C; Files, D Clark; Gibbs, Kevin W; Stubblefield, William B; Casey, Jonathan D; Rice, Todd W; Grijalva, Carlos G; Hager, David N; Shehu, Arber; Qadir, Nida; Chang, Steven Y; Wilson, Jennifer G; Gaglani, Manjusha; Murthy, Kempapura; Calhoun, Nicole; Monto, Arnold S; Martin, Emily T; Malani, Anurag; Zimmerman, Richard K; Silveira, Fernanda P; Middleton, Donald B; Zhu, Yuwei; Wyatt, Dayna; Stephenson, Meagan; Baughman, Adrienne; Womack, Kelsey N; Hart, Kimberly W; Kobayashi, Miwako; Verani, Jennifer R; Patel, Manish M; Amosu, Omowunmi; Armbruster, Brent; Aston, Valerie; Bernardo, Marianne; Bowers, Robert; De Souza, Leslie; Friedel, Jennifer; Gardner, Kevin; Goff, Jennifer; Gordon, Alexandra June; Hendrickson, Audrey; Hicks, Madeline; Howell, Michelle; Johnson, Jakea; Jorgensen, Jeffrey; Karow, Sarah; Kozikowski, Lori; Krol, Olivia; Landreth, Leigha; LaRose, Mary; Lopez, Brenda; York, New; Luong, Andrea; McClellan, Bob; Maruggi, Ellen; Miller, Karen; Nair, Rahul; Parks, Lisa; Peers, Jennifer; Perez, Cynthia; Rivera, Adreanne; Roque, Jonasel; Santana, Andres; Scharber, Tyler; Silverman, Emma; Tozier, Michael; Tzehaie, Hiwet; Zouyed, Zachary; Arroliga, Alejandro; Bagiatis, Alicia; Balasubramani, GK; Cheng, Caroline K; Eng, Heather; Ghamande, Shekhar; Herrick, Judy; Hoffman, Eric; Hughes, Kailey; Lamerato, Lois E; Lauring, Adam S; McKillop, Amanda; McNeal, Tresa; McSpadden, EJ; Midturi, John; Mutnal, Manohar; Nowalk, Mary Patricia
Source
MMWR Morbidity and Mortality Weekly Report. 70(18)
Subject
Language
Abstract
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.